Aurinia Pharmaceuticals Inc. Current Assets
Aurinia Pharmaceuticals Inc. (AUPH) had Current Assets of $541.32 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:AssetsCurrent · last filed 2026-08-06
- 2026-06-30: Assets, Current $541.32M.
- 2026-03-31: Assets, Current $480.24M.
- 2025-12-31: Assets, Current $491.97M.
- 2025-09-30: Assets, Current $438.74M.
| Period end | Assets, Current |
|---|---|
| 2026-06-30 | $541.32M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $480.24M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $491.97M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $438.74M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $408.97M 10-Q · filed 2025-07-31 |
| 2025-03-31 | $405.76M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $446.60M 10-K · filed 2026-02-26 |
| 2024-09-30 | $440.46M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $409.67M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $398.22M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $424.80M 10-K · filed 2025-02-27 |
| 2023-09-30 | $426.47M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $415.91M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $423.65M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $442.54M 10-K · filed 2024-02-15 |
| 2022-09-30 | $459.70M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $453.19M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $477.62M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $513.32M 10-K · filed 2023-02-28 |
| 2021-09-30 | $329.22M 10-Q · filed 2021-11-03 |
| 2021-06-30 | $349.69M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $372.25M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $419.43M 10-K · filed 2022-02-28 |
| 2019-12-31 | $315.14M 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B |